Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
NCT ID: NCT00569504
Last Updated: 2009-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2007-12-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea
NCT01477918
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
NCT00584519
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
NCT00717509
The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome
NCT02093858
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
NCT00937755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
we are planning to enroll approximately 1000 patients with schizophrenia.
For each subject
* abdominal circumference
* body mass index
* lipid profile : TG, HDL-chlo, total chol
* systolic/diastolic blood pressure
* fasting blood glucose will be measured.
we will calculate the rates of patients who meet the criteria for the Metabolic syndrome.
1. Abdominal obesity : absolute criteria
2. 2 or more of followings
1. Triglyceride ≥ 150mg/dL or ongoing treatment
2. HDL-cholesterol \< 40mg/dL (men) HDL-cholesterol \< 50mg/dL (female) or ongoing treatment
3. Hypertension 130mmHg ≥ systolic 85mmHg ≥ diastolic or ongoing treatment
4. FBS ≥ 100mg/dL or previous diagnosis of type II DM
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A, observatoin
inpatients and outpatients in Seoul National Hospital
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* schizophrenia or schizoaffective disorder
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
Seoul National Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seoul National Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jong-il Lee, M.D.
Role: STUDY_DIRECTOR
Seoul National Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMSPSTA
Identifier Type: -
Identifier Source: secondary_id
snh001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.